Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of three systematic review(s)/meta-analysis(es). ^[1-3]
• Progression-Free Survival (PFS): Elotuzumab demonstrated improved PFS in multiple myeloma (MM) patients, including those with the +1q cytogenetic abnormality. Comparative treatments like lenalidomide (Myeloma XI), selinexor (BOSTON), and isatuximab (IKEMA and ICARIA) also showed PFS benefits in the +1q subgroup, while PFS improvement with carfilzomib (Myeloma XI+) and bortezomib (HOVON-65/GMMG-HD4) had wider confidence intervals, indicating result uncertainty.
• Response Rates: In the elotuzumab, lenalidomide, and dexamethasone triplet, complete response rates (CRR) ranked lower than other treatments, while the combination of pomalidomide, bortezomib, and dexamethasone achieved the highest PFS and objective response rates (ORR). The daratumumab, lenalidomide, and dexamethasone regimen was noted for its high probability of the best PFS and ORR outcomes.
• Outcome Measure Sensitivity: Treatment rankings varied when comparing hazard ratios for PFS against CRR, highlighting that the choice of outcome measure (PFS versus CRR) impacts relative treatment rankings.
• The safety data on elotuzumab in the reviewed studies is limited, with no specific safety concerns or adverse effects reported directly related to elotuzumab. However, there is a general caution about the potential for new toxicities associated with monoclonal antibodies in multiple myeloma treatments, highlighting the need for ongoing evaluation.
• Patients with relapsed/refractory multiple myeloma (RRMM), including those with the +1q cytogenetic abnormality, showed a direction of benefit in PFS with elotuzumab and other treatments, though the +1q subgroup exhibited worse overall survival and PFS outcomes across treatment arms in six studies reporting hazard ratios.